Advisor Group’s Insight Molecular Diagnostics IMDX Stock Holding History

Advisor Group’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$1K	Sell	13 -62	-83%	-$2.24K	﹤0.01%	5170
2019 Q3	$4K	Hold	75	–	–	﹤0.01%	4764
2019 Q2	$4K	Buy	75 +64	+582%	+$5.32K	﹤0.01%	4771
2019 Q1	$1K	Buy	11 +10	+1,000%	+$645	﹤0.01%	5099
2018 Q4	$0	Hold	1	–	–	﹤0.01%	5186
2018 Q3	$0	Hold	1	–	–	﹤0.01%	5177
2018 Q2	$0	Hold	1	–	–	﹤0.01%	5005
2018 Q1	$0	Sell	1 -5	-83%	-$330	﹤0.01%	5028
2017 Q4	$1K	Hold	6	–	–	﹤0.01%	4843
2017 Q3	$1K	Buy	6 +1	+20%	+$105	﹤0.01%	4700
2017 Q2	$1K	Buy	+5	New	+$569	﹤0.01%	4647

Other funds holding IMDX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

PAWC

P.A.W. Capital Greenwich, Connecticut $131M AUM 35.16% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Advisor Group's IMDX Position: Q4 2019 in Review

Advisor Group reduced its Insight Molecular Diagnostics (IMDX) stake by 83% in Q4 2019, selling an estimated $2.24K and leaving 13 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #5170.

Advisor Group first reported a position in IMDX in Q2 2017 and has held it in 11 quarters since. The position peaked at $4K in Q3 2019. 56 funds tracked by Wall St. Rank hold IMDX as of Q4 2019.

Advisor Group held 13 shares of Insight Molecular Diagnostics worth $1K as of Q4 2019.
Advisor Group sold 62 Insight Molecular Diagnostics shares in Q4 2019, an estimated $2.24K.
Insight Molecular Diagnostics made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #5170 holding.
Advisor Group first reported a position in Insight Molecular Diagnostics in Q2 2017 and has held it in 11 quarters since.
Advisor Group's Insight Molecular Diagnostics position peaked at $4K in Q3 2019.
56 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.